Literature DB >> 31996296

Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.

J K Pine1, B Haugk2, S M Robinson3, A Darne2, C Wilson3, G Sen3, J J French3, S A White3, D M Manas3, R M Charnley3.   

Abstract

BACKGROUND: Surgical resection remains the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). The prognostic value of resection margin status following pancreatoduodenectomy (PD) remains controversial. Standardised pathological assessment increases positive margins but limited data is available on the significance of involved margins. We investigated the impact of resection margin status in PDAC on patient outcome.
METHOD: We identified all patients with PD for PDAC at one pancreatic cancer centre between August 2008 and December 2014. Demographic, operative, adjuvant therapeutic and survival data was obtained. Pathology data including resection margin status of specific anatomic margins was collected and analysed.
RESULTS: 107 patients were included, all pathologically staged as T3 with 102 N1. 87.9% of patients were R1 of which 53.3% showed direct extension to the resection margin. Median survival for R0 patients versus R1<1 mm and R1 = 0 mm was 28.4 versus 15.4 and 25.1 versus 13.4 months. R1 = 0 mm status remained a predictor of poor outcome on multivariate analysis. Evaluation of individual margins (R1<1 mm) showed the SMV and SMA margins were associated with poorer overall survival. Multiple involved margins impacted negatively on outcome. SMA margin patient outcome with R1 = 1-1.9 mm was similar to R1=>2 mm.
CONCLUSION: Using an R1 definition of <1 mm and standardised pathology we demonstrate that R1 rates in PDAC can approach 90%. R1 = 0 mm remained an independent prognostic factor for overall survival. Using R1<1 mm we have shown that involvement of medial margins and multiple margins has significant negative impact on overall survival. We conclude that not all margin positivity has the same prognostic significance. Crown
Copyright © 2020. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma; Resection margins

Mesh:

Year:  2020        PMID: 31996296     DOI: 10.1016/j.pan.2020.01.004

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  The Role of Pathological Method and Clearance Definition for the Evaluation of Margin Status after Pancreatoduodenectomy for Periampullary Cancer. Results of a Multicenter Prospective Randomized Trial.

Authors:  Gennaro Nappo; Domenico Borzomati; Alessandro Zerbi; Paola Spaggiari; Ugo Boggi; Daniela Campani; Sławomir Mrowiec; Łukasz Liszka; Alessandro Coppola; Michela Amato; Tommasangelo Petitti; Fabio Vistoli; Marco Montorsi; Giuseppe Perrone; Roberto Coppola; Damiano Caputo
Journal:  Cancers (Basel)       Date:  2021-04-26       Impact factor: 6.639

2.  Impact of intraoperative margin clearance on survival following pancreatoduodenectomy for pancreatic cancer: a systematic review and meta-analysis.

Authors:  Emrullah Birgin; Erik Rasbach; Patrick Téoule; Felix Rückert; Christoph Reissfelder; Nuh N Rahbari
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

3.  Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis.

Authors:  Carl Stephan Leonhardt; Willem Niesen; Eva Kalkum; Rosa Klotz; Thomas Hank; Markus Wolfgang Büchler; Oliver Strobel; Pascal Probst
Journal:  BJS Open       Date:  2022-03-08

4.  Impact of prior biliary stenting on diagnostic performance of endoscopic ultrasound for mesenteric vascular staging in patients with head of pancreas and periampullary malignancy.

Authors:  Kofi W Oppong; Manu K Nayar; Noor L H Bekkali; Pardeep Maheshwari; Beate Haugk; Antony Darne; Derek M Manas; Jeremy J French; Steven White; Gourab Sen; Sanjay Pandanaboyana; Richard M Charnley; John S Leeds
Journal:  BMJ Open Gastroenterol       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.